Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-Coagulation factor VII/F7 Antibody-HRP (5U957) is a HRP-conjugated Rabbit antibody targeting Coagulation factor VII/F7. Anti-Coagulation factor VII/F7 Antibody-HRP (5U957) can be used in ELISA.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 μg | $411 | 7-10 days |
Description | Anti-Coagulation factor VII/F7 Antibody-HRP (5U957) is a HRP-conjugated Rabbit antibody targeting Coagulation factor VII/F7. Anti-Coagulation factor VII/F7 Antibody-HRP (5U957) can be used in ELISA. |
Alias | SPCA, coagulation factor VII (serum prothrombin conversion accelerator), Coagulation factor VII, Coagulation factor 7 |
Ig Type | Monoclonal Rabbit IgG |
Clone | 5U957 |
Reactivity | Mouse |
Application | ELISA |
Recommended Dose | ELISA: 0.1-1 μg/ml |
Antibody Type | Monoclonal |
Host Species | Rabbit |
Construction | This antibody was obtained from a rabbit immunized with purified, recombinant Mouse FVII (rM FVII; NP_034302.2Met 1-Leu 446), and conjugated with horseradish-peroxidase (HRP). |
Purification | Protein A |
Appearance | Liquid |
Formulation | 0.2 μm filtered solution in PBS |
Research Background | Coagulation factor VII, also known as Serum prothrombin conversion accelerator, Factor VII, F7 and FVII, is a member of the peptidase S1 family. Factor VII is one of the central proteins in the coagulation cascade. It is an enzyme of the serine protease class, and Factor VII (FVII) deficiency is the most frequent among rare congenital bleeding disorders. Factor VII contains two EGF-like domains, one Gla (gamma-carboxy-glutamate) domain and one peptidase S1 domain. The main role of factor VII is to initiate the process of coagulation in conjunction with tissue factor (TF). Tissue factor is found on the outside of blood vessels, normally not exposed to the blood stream. The action of the Factor VII is impeded by tissue factor pathway inhibitor (TFPI), which is released almost immediately after initiation of coagulation. Factor VII is vitamin K dependent and is produced in the liver. Upon vessel injury, tissue factor is exposed to the blood and circulating Factor VII. Once bound to TF, FVII is activated to FVIIa by different proteases, among which are thrombin (factor IIa), factor Xa, IXa, XIIa, and the FVIIa-TF complex itself. Recombinant activated factor VII (rFVIIa) is a haemostatic agent, which was originally developed for the treatment of haemophilia patients with inhibitors against factor FVIII or FIX. FVIIa binds specifically to endothelial protein C receptor (EPCR), a known cellular receptor for protein C and activated protein C, on the endothelium. rFVIIa is a novel hemostatic agent, originally developed for the treatment of hemorrhage in hemophiliacs with inhibitors, which has been successfully used recently in an increasing number of nonhemophilic bleeding conditions. |
Conjucates | HRP |
Others Formats | Unconjugated |
Antibody Types Available | 2 |
Immunogen | Recombinant Mouse FVII protein |
Antigen Species | Mouse |
Biology Area | Serine Proteases and Regulators |
Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. Keep away from direct sunlight. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.